16 anxiety, depression, PTSD, schizophrenia, opioid addiction, and inflammation in the brain. Further Clinical Studies for epilepsy were conducted at the Ontario Brain Institute by Dr. W McIntyre Burnham, emeritus professor at the University of Toronto. These studies were designed to compare the company’s ‘Drug Candidate, CQ-001’, to standard CBD. The results demonstrated a 50% increase in reduction of seizures. “If people are taking cannabis – or any medication for medicinal purposes – and their receptors are defective or not working at all - the benefits will either be nominal or there will be no indications at all. We wanted to help innovate that space.” Going back to the algae bioreactor timeframe of the company for a moment, it is important to note that at that time CanaQuest discovered most people have significant deficiencies in essential fatty acids, specifically the omegas known as DHA and EPA. Owing to this, most people’s receptors to omega 3 are not working effectively, if at all. When the company conducted its presentation to Dr. Laviolette, prior to him coming on board, it wanted to focus on the combination of DHA and EPA with cannabinoid molecules. This interesting research perspective from the company precipitated Dr Laviolette joining as a scientific partner . His embrace of the scientific approach rubber stamped the company’s intentions to explore the concepts further. Soon it became clear that CanaQuest’s new partner, Dr Laviolette, and his team had made a breakthrough discovery. This consisted of a new pathway into the brain to address mental health neurological conditions and mental ailments. In the preclinical trials, CBD, DHA, and EPA molecules bonded and began to work synergistically. They also attached to the PPAR receptors, facilitating a pathway to cross the blood-brain barrier (BBB) to access a section of the brain responsible for regulating emotions, such as anxiety, depression, and PTSD, with an effect and efficacy that was amplified. The innovation that allowed this to happen was, of course, the formulation consisting of cannabidiol, or CBD, element combined with essential fatty acids, working synergisticly. It is in effect proving the winning validity of a CBD/omega 3 combination. CBD did not manage to achieve this result by itself, in the pre-clinical trial research. Canadian company CanaQuest is a clinical-stage life sciences enterprise. Its focus is directed towards drug discovery and development of the nextgeneration of targeted therapeutics within the endocannabinoid system and specific brain receptors. Its branded medical cannabis product is known as Mentanine®, and is widely available for sale in the United States. CanaQuest has a strong company focal point to bring innovative products to the market, specifically targeted at treating neurological conditions such as epilepsy, anxiety, depression, addiction, and post-traumatic stress disorder. It began life as an algae company, something that is much in demand within the health and beauty industry for its many therapeutic qualities. To this end, it worked professionally alongside a professor at the University of Waterloo, resuling in the construction of an algae bioreactor. This in-depth research led to CanaQuest gaining an understanding about essential fatty acids, often known as omega-3s, which the human body is incapable of producing alone. Despite this, omega-3s are still a necessary component for good health, typically accessed by dietary means such as eating fish, eggs, and/or taking supplements. Following on from its innovative work with algae, CanaQuest was asked if it could extract oils from cannabis. It entered the market with a clear aim to examine cannabis from a scientific perspective. It also wanted to help people, as much as it could. The company had its preclinical trials conducted by the number one neuroscientist in Canada, Dr Steven Laviolette. Dr Laviolette is a professor and neuroscientist at Western University, with decades of experience in the fields of mental health and cannabinoids. Remarkably, the trials demonstrated a decrease in Aug23275 Best Global Medical Cannabinoid Development Company 2023
RkJQdWJsaXNoZXIy MTUyMDQwMA==